Ladenburg Thalmann Maintains Buy on NovoCure, Raises Price Target to $31

Benzinga · 1d ago
Ladenburg Thalmann analyst Kevin DeGeeter maintains NovoCure (NASDAQ:NVCR) with a Buy and raises the price target from $27 to $31.